Looking for a specific product?

Make a search for products & suppliers, articles & news.

Collaboration across the pond develops a new living skin equivalent testing model

Epistem and ScandiDerma announced today that they aim to develop a new in vitro human living skin equivalent model for testing inflammatory responses.


Innovation Norway is the Norwegian Government's most important instrument for innovation and development of Norwegian enterprises and industry. Innovation Norway support companies in developing their competitive advantage and to enhance innovation. Norwegian enterprises have access to a broad business support system as well as financial means. By combining local industry knowledge and international networks with the business ideas and the motivation of entrepreneurs, the foundation for new successful businesses is created. For more information visit www.innovationnorway.com.

Technology Strategy Board is the UK's innovation agency and works to create economic growth by ensuring that the UK is a global leader in innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

This is a novel method that will add to the field of dermatological testing as a whole and help create more activity in extracting high value compounds from biomass. The project will last from May 2013 to March 2014 and will run from the project leader Epistem's facilities in Manchester UK and ScandiDerma's facilities in Barents Biocenter, Tromsø, Norway.

"The collaboration with ScandiDerma presents an exciting opportunity to leverage Epistem's strong scientific background in skin biology and inflammation to address the shortage of robust human dermatology models for testing inflammatory responses" said Matthew Walls, Epistem CEO. 

"For ScandiDerma this is an important milestone in building up our competence around test-systems and how to rapidly determine good lead candidates from our bioprospecting activities" noted Ingebjørg Pernille Nedal, CEO ScandiDerma.

The collaboration is made possible through the UK's innovation agency, the Technology Strategy Board, and Innovation Norway following a successful application for funding in the "Sustainable high value chemical manufacture through industrial biotechnology" competition.

(Source: Marketwire)

Associated companies:

Related news

Latest news

Chairman Knut Ørbeck-Nilssen sets out transformation of IACS at CMA Shipping 2018

To help the maritime community ensure the cyber-resilience of their assets, 

DNV GL opens LNG test centre to enable safer and more efficient use of LNG

The ability to monitor the composition of LNG in real time 

Peter Brun appointed as DNV GL’s new global offshore wind segment leader

Brun brings more than 26 years of experience 

Getting a solid overview of silicon production at Elkem Thamshavn

Major investment by Bremnes Seashore

The contract comprises two Polarcirkel 1050 Cabin, 

Are you in full control of your equipment?

Poorly maintained nets may harm the fish.

Windcat Workboats builds their 19th and 20th vessel with Servogear CPP

The delivery of the Servogear Ecoflow Propulsor to Windcat 43 and Windcat 44 will take place in Q2 and Q4 2018.   

Steinsvik named “Company of the Year 2017”

Development takes time, and this company is a good example of that.

DNV GL primary project partner in Northern Gas Networks led Hydrogen Network Innovation ProjectNv

The project is split into two phases.